LivingGLP1
Study S002208

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

ClinicalTrials.gov recordStudy Protocol (PDF)Informed Consent Form (PDF)

Registration

Registration
NCT07207148
Study type
OBSERVATIONAL
Status
RECRUITING
Enrollment
100
Start
2025-11-15
Primary completion
2028-04-01
Lead sponsor
Northwestern University
Conditions
Multiple Sclerosis
Interventions
DRUG:GLP-1; DRUG:Ocrelizumab (US)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • PIRA [From enrollment to the end of study at 72 weeks.]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0002150Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.
Li M, Sleep
2025Systematic reviewPMID 39626095DOIregistry reference BACKGROUND:39626095
R0016574Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss.
Udawatta M, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025Nonrandomized studyPMID 39030327DOIregistry reference BACKGROUND:39030327
R0007740Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, The New England journal of medicine
2024Randomized trialPMID 38598572DOIregistry reference BACKGROUND:38598572
R0009316Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain.
Diz-Chaves Y, Neural regeneration research
2024Narrative reviewPMID 38103230DOIregistry reference BACKGROUND:38103230
R0008068Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, The New England journal of medicine
2023Randomized trialPMID 37952131DOIregistry reference BACKGROUND:37952131
R0021742Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.
Sadek MA, International immunopharmacology
2023PreclinicalPMID 36584570DOIregistry reference BACKGROUND:36584570
R0023399Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, The New England journal of medicine
2021Randomized trialPMID 33567185DOIregistry reference BACKGROUND:33567185